The Medicare Payment Advisory Commission (MedPAC) convened a session to discuss the Commission’s workplan to analyze generic drug prices in Medicare Part D. MedPAC staff detailed that the Commission is currently examining generic drug prescription drug event (PDE) data, as well as interviewing pharmaceutical supply chain stakeholders to determine factors that impact generic drugs being priced higher in Medicare than… (Slifer, October 6, 2023) #Generic Drugs, #Medicare Part D, #Prescription Drugs